Issuance of U.S. Patent Quantifying Intratumor Spatial Heterogeneity

The newly issued U.S. Patent No. 10,755,138 covers the application of point-wise mutual information maps to quantify spatial intratumor heterogeneity and identify diagnostic regions of interest in tissue samples. This patent has been exclusively licensed to PredxBio, Inc. from the University of Pittsburgh and further adds to the strong and growing IP portfolio of PredxBio […]

TumorMapr @ Nature Communications

Read our latest paper on TumorMapr and see how spatial analytics can reshape understanding cancer, published in Nature Communications : Read here ->

Partnership with CellNetix To Validate Explainable AI Platform for Breast Cancer

Together with CellNetix Pathology & Laboratories, we have announced a collaboration to validate the HistoMapr-Breast™ Platform, which taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose and treat breast cancer more efficiently and accurately. The platform is the first in our larger efforts to harness the power of xAI-assisted lab processes […]

TumorMapr Poster at AACR

PredxBio Announces the Presentation of an Explainable AI Platform (TumorMapr™) that Provides a Mechanistic Understanding of the Risk Recurrence in Solid Tumors Using Hyperplexed Fluorescence Data Sets at the American Association for Cancer Research (AACR) Annual Meeting on April 1, 2019.

NSF SBIR Phase I award for HistoMapr!

PredxBio Awarded Competitive Phase I SBIR Grant from National Science Foundation to Apply Explainable Artificial Intelligence to Breast Pathology.

PredxBio Launched

PredxBio, Inc., which leverages AI for digital pathology markets, announced the launch of company with the recent closing of a seed financing round led by Newlin Investment Company, an early-stage venture capital firm.

Submit your Resume

Download Whitepaper

Download Whitepaper

Subscribe to our Newsletter

* indicates required

B. Dusty Majumdar, PhD


B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

Bruce Campbell, MS

VP Software Engineering

Bruce leads the software engineering and quality assurance teams at PredxBio. As the VP of Software Engineering, he is responsible for analytical infrastructure, product development and the commercialization of machine learning, image processing, and computational biology algorithms. Prior to joining PredxBio, Bruce was at IBM and Xylem in global Director of Data Science roles. He has over 20 years of experience in digital pathology algorithms and is highly motivated to deliver care through digital and computational pathology. He has multiple successful FDA 510k device applications, and multiple CLIA certified algorithms deployed in clinical practice.

Bruce holds a BS in Physics and MS in Applied Mathematics from the University of Rochester, an MS in Statistics from North Carolina State University, and is currently pursuing graduate mathematics studies at The Ohio State University. Bruce loves the outdoors. You can find him hiking and rock climbing in Appalachia.